Eli Lilly and Company will present new clinical data for Foundayo, Mounjaro and retatrutide at the American Diabetes Association’s 86th Scientific Sessions in New Orleans, placing its approved and investigational cardiometabolic portfolio at the centre of the next phase of competition in diabetes and obesity care. The data package includes Phase 3 ACHIEVE results for Foundayo in type 2 diabetes, pivotal retatrutide results in obesity and type 2 diabetes, and additional Mounjaro analyses focused on quality of life and early diabetes outcomes.

The announcement is not simply another evidence update in a fast-moving therapeutic category. It shows Eli Lilly and Company trying to widen the competitive battleground from individual blockbuster drugs to a broader treatment ecosystem that spans oral GLP-1 therapy, dual-incretin injectable therapy and a next-generation triple receptor agonist. That matters because the obesity and diabetes market is no longer being shaped only by weight-loss percentages or A1C reduction. It is increasingly being shaped by route of administration, tolerability, patient segmentation, prescriber convenience, payer pressure, and the ability to offer differentiated choices as cardiometabolic disease becomes a long-duration treatment category.

How Foundayo could shift the oral GLP-1 debate if convenience becomes a clinical advantage

Foundayo, the branded form of orforglipron, is being positioned as a once-daily oral GLP-1 receptor agonist that can be taken without food or water restrictions. That detail may look operational at first glance, but it could become commercially important if clinicians and patients view dosing simplicity as a meaningful differentiator in chronic obesity and diabetes management.

The ACHIEVE program data being presented at the American Diabetes Association meeting gives Eli Lilly and Company a stronger platform to argue that oral GLP-1 therapy can be both convenient and clinically competitive. In ACHIEVE-2, Foundayo lowered A1C by up to 1.7% compared with 0.8% for dapagliflozin at 40 weeks. In ACHIEVE-3, Foundayo outperformed oral semaglutide in type 2 diabetes, delivering better A1C reduction and 73.6% greater relative weight loss at 52 weeks. In ACHIEVE-5, Foundayo lowered A1C by up to 2.1% compared with 0.8% for placebo when used with insulin glargine at 40 weeks.

The strategic significance is clear. Injectable GLP-1 and incretin therapies have already changed the commercial centre of gravity in obesity and diabetes. However, a convenient oral medicine that demonstrates competitive metabolic outcomes could expand the reachable patient pool, especially among those who delay or avoid injectable therapy. For primary care physicians, endocrinologists and payers, a credible oral option may also help create more flexible treatment sequencing.

The unresolved question is whether convenience alone will translate into sustained market share if pricing, gastrointestinal tolerability, adherence patterns and payer controls become more restrictive. Oral therapies can expand access, but they can also face different adherence challenges because daily dosing creates more opportunities for missed treatment. Foundayo’s lack of food and water restrictions may reduce friction, but long-term persistence data will matter as much as headline trial efficacy.

Why retatrutide may raise the bar for next-generation obesity and diabetes drugs

Retatrutide is arguably the most strategically important investigational asset in this data package because it moves Eli Lilly and Company beyond the current dual-incretin model and into triple receptor agonism. The investigational once-weekly medicine activates GIP, GLP-1 and glucagon receptors, giving it a mechanistic profile designed to influence weight, glucose metabolism and broader cardiometabolic risk.

The Phase 3 TRIUMPH-1 results showed average weight loss of up to 70.3 pounds, or 28.3%, at 80 weeks in adults with obesity. In TRANSCEND-T2D-1, retatrutide reduced A1C by up to an average of 2.0% and body weight by up to 36.6 pounds, or 16.8%, at 40 weeks in adults with type 2 diabetes. Those figures strengthen the perception that the next wave of obesity medicines may push clinical expectations beyond the first generation of GLP-1 and dual-incretin therapies.

For industry observers, the critical point is not just whether retatrutide produces larger average weight loss. It is whether higher efficacy can be achieved with a tolerability, safety and discontinuation profile that supports real-world chronic use. The obesity market is already moving from proof of concept to long-term disease modification. That means regulators, payers and clinicians will increasingly focus on whether deep weight loss can be maintained safely, whether benefits extend to cardiovascular and renal outcomes, and whether treatment can be scaled without overwhelming health budgets.

Retatrutide also raises a competitive question for Eli Lilly and Company’s own portfolio. If the medicine eventually reaches the market with superior efficacy, it could reinforce the company’s leadership but also force careful positioning against Mounjaro and Zepbound. A powerful next-generation asset can protect a franchise, but it can also reshape treatment expectations faster than payers and health systems are prepared to absorb.

How Mounjaro data keeps tirzepatide relevant as Lilly builds beyond its current blockbuster base

Mounjaro remains central to Eli Lilly and Company’s cardiometabolic franchise even as investor attention shifts toward Foundayo and retatrutide. The new poster presentations from SURPASS-CVOT and SURPASS-EARLY focus less on headline weight loss and more on quality of life, daily functioning and early type 2 diabetes outcomes.

That is strategically useful because the GLP-1 and incretin market is maturing. In early adoption phases, weight-loss efficacy and glucose lowering tend to dominate the narrative. As treatment moves into broader clinical practice, quality of life, functional improvement and long-term disease burden become more important to clinicians, payers and patients. Data showing improvement in physical, psychosocial and daily functioning outcomes can help support a broader value story around tirzepatide.

The limitation is that quality-of-life findings can be harder to translate into reimbursement advantage than hard outcomes such as cardiovascular risk reduction, renal benefit or durable diabetes remission signals. Payers may welcome broader patient-reported benefits, but they are likely to keep demanding evidence that expensive cardiometabolic medicines reduce downstream medical costs. Mounjaro therefore remains commercially powerful, but the next stage of its value story will need to link clinical benefit with health-system economics.

Why menopause subgroup data may open a more targeted obesity care conversation

The ATTAIN subgroup analysis for Foundayo showed significant weight loss across all stages of menopause, including more than 14% weight reduction in women with peri-menopause or post-menopause in ATTAIN-1. This may prove important because obesity treatment is increasingly moving toward more precise patient segmentation rather than one-size-fits-all prescribing.

Women in peri-menopause and post-menopause represent a clinically important population because weight gain, insulin resistance, metabolic changes and cardiovascular risk can intensify during this life stage. If Foundayo continues to show meaningful weight reduction across menopause subgroups, Eli Lilly and Company could have a stronger basis for clinician education and targeted real-world evidence generation in a population that is often central to cardiometabolic care.

The risk is that subgroup data can be overinterpreted if it is not supported by robust trial design, adequate representation and longer-term outcomes. Clinicians will want to know whether the observed benefits are consistent across age, baseline body mass index, metabolic status, hormone therapy use and comorbid conditions. The commercial opportunity is real, but the scientific bar for population-specific claims remains high.

What the broader Lilly portfolio says about the future of cardiometabolic treatment choice

Eli Lilly and Company’s cardiometabolic strategy is increasingly built around treatment choice. Zepbound addresses chronic weight management and obesity-related obstructive sleep apnea. Mounjaro anchors type 2 diabetes treatment with dual GIP and GLP-1 receptor activity. Foundayo aims to bring a convenient oral GLP-1 option into obesity and diabetes care. Retatrutide is being developed across obesity, type 2 diabetes, sleep apnea, knee osteoarthritis, chronic low back pain, cardiovascular and renal outcomes, and metabolic dysfunction-associated steatotic liver disease.

That breadth gives Eli Lilly and Company a strategic advantage because cardiometabolic disease is not a single-market opportunity. It is a cluster of overlapping chronic conditions where obesity, diabetes, cardiovascular risk, liver disease, sleep apnea and musculoskeletal burden often interact. A broad portfolio allows the company to build multiple entry points into the same patient ecosystem.

The commercial challenge is that breadth can also create complexity. Physicians will need clear guidance on which medicine fits which patient. Payers will need evidence to justify coverage across different indications. Regulators will scrutinise safety across longer treatment durations and broader patient populations. Manufacturing capacity will remain a major practical factor because demand for high-performing obesity and diabetes medicines continues to stretch supply chains.

Why the real test will be durability, access and payer acceptance rather than efficacy alone

The latest data reinforce Eli Lilly and Company’s position as one of the most important players in cardiometabolic medicine, but the next phase of the market will not be decided by trial efficacy alone. Durability of response, long-term safety, discontinuation rates, cardiovascular outcomes, patient adherence, cost-effectiveness and supply reliability will decide how much of the clinical promise becomes real-world adoption.

Foundayo may appeal to patients and physicians looking for an oral GLP-1 option without restrictive dosing requirements. Retatrutide may push the efficacy frontier higher if its Phase 3 profile continues to hold up across indications. Mounjaro may remain a foundational therapy if its broader outcome and quality-of-life story strengthens. Together, these assets give Eli Lilly and Company a formidable portfolio, but they also create a high-expectation environment where every new dataset will be judged against rising standards.

For clinicians, the most important question will be how these medicines fit into practical treatment pathways. For regulators, the focus will be long-term safety and label clarity. For payers, the question will be whether broader access can be justified by measurable reductions in downstream disease burden. For competitors, the message is blunt: the obesity and diabetes market is becoming less about having one strong GLP-1 drug and more about building a full cardiometabolic platform.

  diabetes, Eli Lilly and Company, Foundayo, GLP-1, Mounjaro, obesity, orforglipron, retatrutide, tirzepatide, Zepbound